2021
(E)-3-furan-2-yl-N-phenylacrylamide (PAM-4) decreases nociception and emotional manifestations of neuropathic pain in mice by α7 nicotinic acetylcholine receptor potentiation
Bagdas D, Sevdar G, Gul Z, Younis R, Cavun S, Tae HS, Ortells MO, Arias HR, Gurun MS. (E)-3-furan-2-yl-N-phenylacrylamide (PAM-4) decreases nociception and emotional manifestations of neuropathic pain in mice by α7 nicotinic acetylcholine receptor potentiation. Neurological Research 2021, 43: 1056-1068. PMID: 34281483, DOI: 10.1080/01616412.2021.1949684.Peer-Reviewed Original ResearchConceptsPositive allosteric modulationΑ7 nAChRsNeuropathic painΑ7-selective antagonist methyllycaconitineΑ7 nicotinic acetylcholine receptorChronic constriction injuryPaw licking behaviorNeuropathic pain modelAcute systemic administrationChronic painful conditionsAntidepressant-like activityAnti-nociceptive activityDepression-like behaviorAnxiogenic-like effectsNicotinic acetylcholine receptorsAffective behaviorHuman α7 nAChRConstriction injuryMechanical allodyniaFormalin testPain modelAntagonist methyllycaconitineChronic painPainful conditionsRat α7 nAChR
2020
Pharmacologic Overview of Chlorogenic Acid and its Metabolites in Chronic Pain and Inflammation
Bagdas D, Gul Z, Meade JA, Cam B, Cinkilic N, Gurun MS. Pharmacologic Overview of Chlorogenic Acid and its Metabolites in Chronic Pain and Inflammation. Current Neuropharmacology 2020, 18: 216-228. PMID: 31631820, PMCID: PMC7327949, DOI: 10.2174/1570159x17666191021111809.Peer-Reviewed Original ResearchConceptsLiterature searchElectronic literature searchDifferent pathological situationsChlorogenic acidPharmacologic overviewNeuropathic painPain managementChronic painInflammatory insultPreventive roleAnimal modelsInflammationPotent antioxidantCertain foodsOxidative stressEthnopharmacological reportsPutative mechanismsDietary plantsAntioxidant defenseNatural phenolic compoundsPathological situationsPainMedicinal herbsOriginal articlesPhenolic compounds
2019
Pharmacological mechanisms of alcohol analgesic-like properties in mouse models of acute and chronic pain
Neddenriep B, Bagdas D, Contreras K, Ditre J, Wolstenholme J, Miles M, Damaj M. Pharmacological mechanisms of alcohol analgesic-like properties in mouse models of acute and chronic pain. Neuropharmacology 2019, 160: 107793. PMID: 31562845, PMCID: PMC6924270, DOI: 10.1016/j.neuropharm.2019.107793.Peer-Reviewed Original ResearchConceptsAnalgesic-like propertiesComplete Freund's adjuvantAnti-nociceptive propertiesChronic painNeuropathic painChronic constriction injury modelAlcohol useMu-opioid systemOral ethanol administrationPain-like statePeripheral neuropathic painNeuropathic pain modelKappa-selective antagonistAcute alcohol useAnalgesic-like effectsDose-dependent reversalMechanical hypersensitivityAnalgesic effectNerve injuryPain modelAcute modelOpioid systemAcute alcoholFreund's adjuvantChronic use
2018
The antinociceptive and anti-inflammatory properties of the α7 nAChR weak partial agonist p-CF3 N,N-diethyl-N’-phenylpiperazine
Quadri M, Bagdas D, Toma W, Stokes C, Horenstein N, Damaj M, Papke R. The antinociceptive and anti-inflammatory properties of the α7 nAChR weak partial agonist p-CF3 N,N-diethyl-N’-phenylpiperazine. Journal Of Pharmacology And Experimental Therapeutics 2018, 367: jpet.118.249904. PMID: 30111636, PMCID: PMC7593094, DOI: 10.1124/jpet.118.249904.Peer-Reviewed Original ResearchConceptsAntinociceptive activitySelective antagonist methyllycaconitineAnti-inflammatory therapyAnti-inflammatory componentsAnti-inflammatory propertiesPositive allosteric modulatorsNon-neuronal cellsNicotinic acetylcholine receptorsVivo antinociceptive activityAntiedema effectInflammatory painAntagonist methyllycaconitineChronic painInflammatory diseasesHeteromeric nAChRsReceptor subtypesElectrophysiological profileNoncompetitive antagonistAcetylcholine receptorsAgonist activityPartial agonistAllosteric modulatorsSuch drugsPromising drug targetSilent agonistNew Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs
Bagdas D, Gurun M, Flood P, Papke R, Damaj M. New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs. Current Neuropharmacology 2018, 16: 415-425. PMID: 28820052, PMCID: PMC6018191, DOI: 10.2174/1570159x15666170818102108.Peer-Reviewed Original ResearchConceptsNicotinic acetylcholine receptorsΑ7 nAChRsAcetylcholine receptorsNeuronal nicotinic acetylcholine receptorsPerspective of painChronic pain conditionsTreatment of painRecent animal studiesPain controlPain conditionsSide effectsAnimal studiesTherapeutic targetingPainReceptor typesNAChRsReceptorsInflammationSelective ligandsΑ7Latest findingsTreatmentRecent insightsReviewNicotine
2015
The Antinociceptive and Antiinflammatory Properties of 3-furan-2-yl-N-p-tolyl-acrylamide, a Positive Allosteric Modulator of &agr;7 Nicotinic Acetylcholine Receptors in Mice
Bagdas D, Targowska-Duda K, López J, Perez E, Arias H, Damaj M. The Antinociceptive and Antiinflammatory Properties of 3-furan-2-yl-N-p-tolyl-acrylamide, a Positive Allosteric Modulator of &agr;7 Nicotinic Acetylcholine Receptors in Mice. Anesthesia & Analgesia 2015, 121: 1369-1377. PMID: 26280585, PMCID: PMC4847442, DOI: 10.1213/ane.0000000000000902.Peer-Reviewed Original ResearchConceptsPositive allosteric modulatorsType II positive allosteric modulatorsNeuropathic pain modelInflammatory painNicotinic acetylcholine receptorsNeuropathic painPain modelCarrageenan testAntiinflammatory propertiesChronic constriction injury-induced neuropathic painAcetylcholine receptorsInjury-induced neuropathic painAllosteric modulatorsΑ7 nicotinic acetylcholine receptorSelective α7 agonistPlace aversion (CPA) testExperience of painEfficacy of agonistsEndogenous neurotransmissionMechanical allodyniaThermal hyperalgesiaTime-dependent mannerAntinociceptive effectComplete Freund'sPaw edema
2014
Antinociceptive Effect of Chlorogenic Acid in Rats with Painful Diabetic Neuropathy
Bagdas D, Ozboluk H, Cinkilic N, Gurun M. Antinociceptive Effect of Chlorogenic Acid in Rats with Painful Diabetic Neuropathy. Journal Of Medicinal Food 2014, 17: 730-732. PMID: 24611441, DOI: 10.1089/jmf.2013.2966.Peer-Reviewed Original ResearchConceptsDiabetic neuropathic painAntinociceptive effectNeuropathic painChronic treatmentPainful diabetic neuropathyPossible antinociceptive effectSignificant antinociceptive effectChlorogenic acid treatmentChlorogenic acidDiabetic neuropathyNondiabetic ratsDiabetic ratsSingle doseAntinociceptive potentialRatsBeneficial effectsPainTreatmentPresent studyNeuropathyStreptozotocinHyperglycemiaDiabetesDose
2013
Role of central arginine vasopressin receptors in the analgesic effect of CDP-choline on acute and neuropathic pain
Bagdas D, Yucel-Ozboluk H, Orhan F, Kanat O, Isbil-Buyukcoskun N, Gurun M. Role of central arginine vasopressin receptors in the analgesic effect of CDP-choline on acute and neuropathic pain. Neuroreport 2013, 24: 941-946. PMID: 24089014, DOI: 10.1097/wnr.0000000000000009.Peer-Reviewed Original ResearchConceptsCentral AVP receptorsAnalgesic effectAVP V1Pain modelAVP receptorsChronic constriction injury-induced neuropathic pain modelCDP-cholineDifferent pain modelsRandall-Selitto testNeuropathic pain modelAVP V2 receptorsV2 receptor antagonistAVP V2 receptor antagonistArginine vasopressin receptorsNeuropathic painNeuropathic modelsPain modulationIntracerebroventricular injectionPain thresholdReceptor antagonistVasopressin levelsV2 receptorsVasopressin receptorsRatsReceptorsPreclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain.
Kanat O, Bagdas D, Ozboluk H, Gurun M. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. JBUON 2013, 18: 1012-8. PMID: 24344031.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesicsAnimalsCytidine Diphosphate CholineDisease Models, AnimalDose-Response Relationship, DrugGABA-B Receptor AntagonistsHyperalgesiaInjections, IntraventricularMaleNeuralgiaNeurotransmitter Uptake InhibitorsNicotinic AntagonistsOrganoplatinum CompoundsOxaliplatinPain ThresholdRatsRats, Sprague-DawleyTime FactorsConceptsAntihyperalgesic effectNeuropathic painCDP-cholineNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneRat paw pressure testReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneOxaliplatin-induced neuropathic painCholine uptake inhibitor hemicholinium-3Induction of neuropathyAntagonist CGP 35348Paw pressure testGamma-amino butyric acidNicotinic acetylcholine receptorsCGP 35348Neuropatic painMechanical hyperalgesiaAntagonist atropineTime-dependent mannerPreclinical evidenceAntagonist naloxoneAntihyperalgesic activity
2012
Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain
Bagdas D, Cinkilic N, Ozboluk H, Ozyigit M, Gurun M. Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain. Journal Of Natural Medicines 2012, 67: 698-704. PMID: 23203628, DOI: 10.1007/s11418-012-0726-z.Peer-Reviewed Original ResearchConceptsChronic constrictive nerve injuryNeuropathic painAntihyperalgesic activityPeripheral neuropathic pain modelExperimental neuropathic painNeuropathic pain modelRota-rod testNovel potential therapeutic optionPotential therapeutic optionStrong therapeutic effectLatency of ratsChlorogenic acidAntihyperalgesic effectMechanical hyperalgesiaNerve injuryPain modelChronic administrationInflammatory cascadeTherapeutic optionsHistopathological changesInflammatory processTherapeutic effectAnalgesic activityPainNervous system
2011
The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models
Bagdas D, Sonat F, Hamurtekin E, Sonal S, Gurun M. The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models. Behavioural Pharmacology 2011, 22: 589-598. PMID: 21836465, DOI: 10.1097/fbp.0b013e32834a1efb.Peer-Reviewed Original ResearchConceptsNeuropathic pain modelAntihyperalgesic effectPain modelChronic constriction injury-induced neuropathic pain modelNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneΓ-aminobutyric acid B receptorsNicotinic ACh receptor antagonistsReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneCholine uptake inhibitor hemicholinium-3CDP-cholineEffect of intracerebroventricularlyAntagonist CGP 35348Central opioid receptorsInflammatory pain modelACh receptor antagonistNicotinic ACh receptorsCGP 35348Mechanical hyperalgesiaNeuropathic painAntagonist atropineAntagonist naloxone
2007
Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats
Hamurtekin E, Bagdas D, Gurun M. Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats. Neuroscience Letters 2007, 420: 116-121. PMID: 17531379, DOI: 10.1016/j.neulet.2007.04.058.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic alpha-AntagonistsAnalgesicsAnimalsBrainCytidine Diphosphate CholineDisease Models, AnimalEfferent PathwaysGABA AntagonistsInjections, IntraventricularMaleNarcotic AntagonistsNociceptorsPainPain MeasurementPain ThresholdRatsRats, Sprague-DawleyReceptors, Adrenergic, alphaReceptors, GABAReceptors, GABA-BReceptors, OpioidReceptors, SerotoninSerotonin AntagonistsConceptsAcute pain modelsMechanical paw pressure testThermal paw withdrawal testPaw pressure testPaw withdrawal testAntinociceptive effectPain modelSupraspinal opioidsSerotonergic receptorsAlpha-1 adrenergic receptor antagonist prazosinCDP-cholineWithdrawal testOpioid receptor antagonist naloxoneAdrenergic receptor antagonist prazosinAdrenergic receptor antagonist yohimbineCytidine-5′-diphosphate cholineDifferent pain modelsExerts antinociceptive effectsDose-dependent antinociceptionReceptor antagonist yohimbineReceptor antagonist prazosinReceptor-mediated mechanismMethysergide pretreatmentAntagonist yohimbineAntagonist prazosin